Insider Selling: Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Insider Sells $13,762.32 in Stock

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) insider Mark Lackner sold 4,411 shares of the firm’s stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $3.12, for a total transaction of $13,762.32. Following the completion of the transaction, the insider now directly owns 191,317 shares in the company, valued at $596,909.04. This represents a 2.25 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link.

Zentalis Pharmaceuticals Stock Up 8.0 %

ZNTL stock opened at $3.24 on Monday. Zentalis Pharmaceuticals, Inc. has a 52-week low of $2.66 and a 52-week high of $18.07. The business has a fifty day moving average of $3.33 and a two-hundred day moving average of $3.50. The stock has a market cap of $230.90 million, a price-to-earnings ratio of -1.30 and a beta of 1.84.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last posted its earnings results on Tuesday, November 12th. The company reported ($0.56) EPS for the quarter, beating analysts’ consensus estimates of ($0.92) by $0.36. As a group, sell-side analysts anticipate that Zentalis Pharmaceuticals, Inc. will post -2.48 EPS for the current year.

Analyst Upgrades and Downgrades

ZNTL has been the topic of a number of research analyst reports. Oppenheimer reaffirmed an “outperform” rating and issued a $20.00 price target on shares of Zentalis Pharmaceuticals in a research note on Monday, September 16th. HC Wainwright reaffirmed a “buy” rating and set a $20.00 price objective on shares of Zentalis Pharmaceuticals in a research note on Friday, November 15th. Finally, Guggenheim dropped their price target on Zentalis Pharmaceuticals from $12.00 to $8.00 and set a “buy” rating for the company in a research report on Friday, November 15th. Five equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and an average target price of $10.00.

Institutional Trading of Zentalis Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ZNTL. Bank of New York Mellon Corp grew its stake in shares of Zentalis Pharmaceuticals by 15.1% in the second quarter. Bank of New York Mellon Corp now owns 333,719 shares of the company’s stock valued at $1,365,000 after buying an additional 43,839 shares in the last quarter. Rhumbline Advisers lifted its position in shares of Zentalis Pharmaceuticals by 13.8% during the second quarter. Rhumbline Advisers now owns 94,213 shares of the company’s stock worth $385,000 after purchasing an additional 11,451 shares in the last quarter. Los Angeles Capital Management LLC boosted its stake in shares of Zentalis Pharmaceuticals by 117.6% in the second quarter. Los Angeles Capital Management LLC now owns 83,717 shares of the company’s stock valued at $342,000 after purchasing an additional 45,249 shares during the period. American Century Companies Inc. acquired a new position in shares of Zentalis Pharmaceuticals in the second quarter valued at approximately $95,000. Finally, Renaissance Technologies LLC increased its stake in Zentalis Pharmaceuticals by 152.6% during the 2nd quarter. Renaissance Technologies LLC now owns 661,682 shares of the company’s stock worth $2,706,000 after buying an additional 399,745 shares during the period.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.